Federal Register / Vol. 62, No. 236 / Tuesday, December 9, 1997 / Notices 64855

Rockledge Drive, Room 4106, Bethesda,

Maryland 20892, (301) 435–1786.

Name of SEP: Biological and Physiological.

Date: December 10, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 6178,

Telephone Conference.

Contact Person: Dr. Nancy Pearson,

Scientific Review Administrator, 6701

Rockledge Drive, Room 6178, Bethesda,

Maryland 20892, (301) 435–1047.

Name of SEP: Biological and Physiological.

Date: December 11, 1997.

Time: 2:00 p.m.

Place: NIH, Rockledge 2, Room 6178,

Telephone Conference.

Contact Person: Dr. Nancy Pearson,

Scientific Review Administrator, 6701

Rockledge Drive, Room 6178, Bethesda,

Maryland 20892, (301) 435–1047.

This notice is being published less than 15

days prior to the above meetings due to the

urgent need to meet timing limitations

imposed by the grant review and funding

cycle.

Name of SEP: Behavioral and

Neurosciences.

Date: January 18, 1998.

Time: 8:30 a.m.

Place: The Williard Hotel, Washington, DC.

Contact Person: Dr. David Simpson,

Scientific Review Administrator, 6701

Rockledge Drive, Room 5192, Bethesda,

Maryland 20892, (301) 435–1278.

The meetings will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Nos. 93.306, 93.333, 93.337, 93.393–

93.396, 93.837–93.844, 93.846–93.878,

93.892, 93.893, National Institutes of Health,

HHS)

Dated: December 2, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–32092 Filed 12–8–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Therapeutic Uses of Blood

Vessel Growth Promoting Peptides

Including Vascular Endothelial Growth

Factor (VEGF) and Basic Fibroblast

Growth Factor (FGF) for

Cardiovascular Disease and

Conditions Such as Myocardial

Ischemia

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i) that the National Institutes

of Health (NIH), Department of Health

and Human Services, is contemplating

the grant of a domestic exclusive license

to practice the inventions embodied in

the patent referred to below to Collateral

Therapeutics of San Diego, California.

The patent rights in these inventions

have been assigned to the government of

the United States of America. The

patent to be licensed is: ‘‘Method To

Foster Myocardial Blood Vessel Growth

And Improve Blood Flow To The

Heart’’, U.S. Patent Application Serial

No. 07/799,830 filed November 27,

1991, which issued as U.S. Patent No.

5,244,460 on September 14, 1993.

DATES: Only written comments and/or

applications for a license which are

received by NIH on or before February

9, 1998 will be considered.

ADDRESSES: Requests for a copy of this

patent, inquiries, comments, and other

materials relating to the contemplated

license should be directed to: J. Peter

Kim, Technology Licensing Specialist,

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; Telephone: (301)

496–7056, ext. 264; Facsimile: (301)

402–0220.

SUPPLEMENTARY INFORMATION: The

present invention relates to

improvements in the treatment of

diseases, and more particularly to

procedures and compositions used to

foster myocardial blood vessel growth

and improve blood flow to the heart.

The present invention provides a

method for facilitating in a damaged

heart or a heart in need of improved

circulation the growth of cardiac blood

vessels while reducing the risk of

undesired vascularization in other areas

of the body. The method comprises: (a)

Inserting a catheter into a coronary

artery and providing an infusion port

accessible to the administration of

coronary drug injections; (b) injecting an

effective amount of a blood vessel

growth promoting peptide into the

heart; and (c) periodically repeating

such injection on subsequent days until

improved cardiac blood flow has been

obtained. The subject invention may be

applied to treating cardiovascular

disease and conditions including

myocardial ischemia and atherosclerosis

of the coronary arteries. Such a therapy

can potentially be used to partially or

completely replace blocked coronary

arteries with new blood vessels without

affecting the degree of vascularity in the

area of the body.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that

establishes that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7

Applications for a license filed in

response to this notice will be treated as

objections to the grant of the

contemplated license. Comments and

objections submitted in response to this

notice will not be made available for

public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552. Copies of the subject

issued patent are available upon

request.

Dated: December 1, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–32088 Filed 12–8–97; 8:45 am]

BILLING CODE 4140–01–M